Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

resources

Lilly


Click here for Trulicity® (dulaglutide) Prescribing Information and Adverse Event Reporting
Click here for Lyumjev® ▼ (insulin lispro) Prescribing Information and Adverse Event Reporting

Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and products complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.

Resources

Resources for online viewing only.

Lyumjev® is indicated for the treatment of diabetes mellitus in adults only.
Lymjev in not indicated for use in children.

Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
• in addition to other medicinal products for the treatment of diabetes mellitus

Company profile

Lilly has been a global leader in diabetes care since 1923. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions – from medicines to support programmes and more – we strive to make life better for all those affected by diabetes around the world.

This content is for UK & ROI Healthcare Professionals only. Lilly has provided sponsorship for the delivery of the conference and have only had input into the symposium sessions which they have sponsored.

For more information, visit www.lillydiabetes.co.uk (Promotional for UK healthcare professionals only).

This content is for UK & ROI Healthcare Professionals only. This resource page and the materials included have been organised and supported by Lilly.

PP-LD-GB-1393 | October 2021

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.